Charles Hearn Hoke, JR
Physician at Cardinal Ln, Columbia, MD
License number
Colorado 20980
Issued Date
Jul 12, 1977
Renew Date
Jun 1, 2003
Expiration Date
May 31, 2005
Type
Physician
Address
Address
6405 Cardinal Ln, Columbia, MD 21044
Professional information
Dr. Charles H Hoke, Fort Detrick MD - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
1430 Veterans Way, Fort Detrick 21702
(301) 619-7844 (Phone), (301) 619-7844 (Fax)
6405 Cardinal Ln, Columbia 21044
(301) 596-3492 (Phone)
(301) 619-7844 (Phone), (301) 619-7844 (Fax)
6405 Cardinal Ln, Columbia 21044
(301) 596-3492 (Phone)
Certifications:
Infectious Disease, 1978, Internal Medicine, 1977, Public Health
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Rochester
Graduated: 1972
Baylor College Of Medicine
U Colo Med Ctr
University of Rochester
Graduated: 1972
Baylor College Of Medicine
U Colo Med Ctr
Multivalent Dengue Virus Vaccine
US Patent:
6638514, Oct 28, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/535117
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
Sun Wellington - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
Sun Wellington - Rockville MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39193
US Classification:
4242181, 4242021
Abstract:
The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.
Attenuated Dengue-4 Virus Vaccine
US Patent:
6537557, Mar 25, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/534726
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39193
US Classification:
4242181, 435236
Abstract:
The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.
Attenuated Dengue-3 Virus Vaccine
US Patent:
6528065, Mar 4, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/535684
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Hayerford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Hayerford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 3912
US Classification:
4242181, 4242041, 4242781
Abstract:
The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.
Attenuated Dengue-2 Virus Vaccine
US Patent:
6511667, Jan 28, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/534725
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Niranian Kanesa-thasan - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Niranian Kanesa-thasan - Rockville MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39193
US Classification:
4242181, 435237
Abstract:
The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.
Infectious Japanese Encephalitis Virus Cdna Clones That Produce Highly Attenuated Recombinant Japanese Encephalitis Virus, And Vaccines Thereof
US Patent:
5736148, Apr 7, 1998
Filed:
May 11, 1995
Appl. No.:
8/438702
Inventors:
Hideo Sumiyoshi - Branford CT
Charles H. Hoke - Columbia MD
Charles H. Hoke - Columbia MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 3912, C12N 704
US Classification:
4242181
Abstract:
cDNA clones containing the entire genome of Japanese encephalitis virus (JEV) were used to produce infectious, recombinant JEV particles with diverse virulence properties. Certain viruses retained the immunogenicity of JEV, but lacked the ability to cause encephalitis. The mutation associated with this loss of neurovirulence was localized to a nucleotide substitution in the codon encoding the 138th amino acid of the envelop protein, resulting in a mutation of an acidic amino acid to a basic amino acid. Attenuated viruses containing this mutation form the basis of a greatly improved, molecularly defined vaccine for the prevention of Japanese encephalitis in humans.
Multivalent Dengue Virus Vaccine
US Patent:
7217418, May 15, 2007
Filed:
Jul 24, 2003
Appl. No.:
10/626315
Inventors:
Kenneth H. Eckels - Rockville MD, US
Joseph B. Putnak - Silver Spring MD, US
Doria R. Dubois - Wheaton MD, US
Bruce L. Innis - Haverford PA, US
Charles H. Hoke - Columbia MD, US
Wellington Sun - Rockville MD, US
Niranjan Kanesa-Thasan - Rockville MD, US
Joseph B. Putnak - Silver Spring MD, US
Doria R. Dubois - Wheaton MD, US
Bruce L. Innis - Haverford PA, US
Charles H. Hoke - Columbia MD, US
Wellington Sun - Rockville MD, US
Niranjan Kanesa-Thasan - Rockville MD, US
Assignee:
United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39/295
US Classification:
4242021, 4242181
Abstract:
The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.
Recombinant Vaccine Made In E. Coli Against Dengue Virus
US Patent:
6117640, Sep 12, 2000
Filed:
May 2, 1995
Appl. No.:
8/433263
Inventors:
Ashok Kumar Srivastava - Silver Spring MD
J. Robert Putnak - Silver Spring MD
Charles H. Hoke - Columbia MD
Richard L. Warren - Brookville MD
J. Robert Putnak - Silver Spring MD
Charles H. Hoke - Columbia MD
Richard L. Warren - Brookville MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 3912, C07H 2104, C07K 1418
US Classification:
435 71
Abstract:
A recombinant protein encompassing a C-terminal protion from the structural envelope glycoprotein and an N-terminal portion from non-structural protein one of dengue type 2 virus was expressed in Escherichia coli as a fusion protein with Staphylococcal protein A. The recombinant protein was found to provide protection against lethal challenge with dengue 2 in mice.